Institution
Dainippon Sumitomo Pharma Co., Ltd.
Company•Osaka, Japan•
About: Dainippon Sumitomo Pharma Co., Ltd. is a company organization based out in Osaka, Japan. It is known for research contribution in the topics: Alkyl & Agonist. The organization has 920 authors who have published 662 publications receiving 14115 citations. The organization is also known as: Dainippon Sumitomo Seiyaku Kabushiki-Gaisha.
Topics: Alkyl, Agonist, Lurasidone, Active ingredient, Receptor
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is demonstrated that the neutral sphyngomyelinase 2 (nSMase2) regulates exosomal microRNA (miRNA) secretion and promotes angiogenesis within the tumor microenvironment as well as metastasis, suggesting that the horizontal transfer of exosome miRNAs from cancer cells can dictate the microenviromental niche for the benefit of the cancer cell.
617 citations
••
TL;DR: The new syngeneic BBB model, which is the first model to incorporate pericytes in a triple co-culture setting, can be a useful tool for research on BBB physiology and pathology and to test candidate compounds for centrally acting drugs.
608 citations
••
TL;DR: It is demonstrated that lurasidone possesses antipsychotic activity and antidepressant- or anxiolytic-like effects with potentially reduced liability for extrapyramidal and CNS depressant side effects.
Abstract: Lurasidone [(3aR,4S,7R,7aS)-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl]hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; SM-13496] is an azapirone derivative and a novel antipsychotic candidate. The objective of the current studies was to investigate the in vitro and in vivo pharmacological properties of lurasidone. Receptor binding affinities of lurasidone and several antipsychotic drugs were tested under comparable assay conditions using cloned human receptors or membrane fractions prepared from animal tissue. Lurasidone was found to have potent binding affinity for dopamine D(2), 5-hydroxytryptamine 2A (5-HT(2A)), 5-HT(7), 5-HT(1A), and noradrenaline alpha(2C) receptors. Affinity for noradrenaline alpha(1), alpha(2A), and 5-HT(2C) receptors was weak, whereas affinity for histamine H(1) and muscarinic acetylcholine receptors was negligible. In vitro functional assays demonstrated that lurasidone acts as an antagonist at D(2) and 5-HT(7) receptors and as a partial agonist at the 5-HT(1A) receptor subtype. Lurasidone showed potent effects predictive of antipsychotic activity, such as inhibition of methamphetamine-induced hyperactivity and apomorphine-induced stereotyped behavior in rats, similar to other antipsychotics. Furthermore, lurasidone had only weak extrapyramidal effects in rodent models. In animal models of anxiety disorders and depression, treatment with lurasidone was associated with significant improvement. Lurasidone showed a preferential effect on the frontal cortex (versus striatum) in increasing dopamine turnover. Anti-alpha(1)-noradrenergic, anticholinergic, and central nervous system (CNS) depressant actions of lurasidone were also very weak. These results demonstrate that lurasidone possesses antipsychotic activity and antidepressant- or anxiolytic-like effects with potentially reduced liability for extrapyramidal and CNS depressant side effects.
364 citations
••
TL;DR: Findings from studies that utilize or rodent studies rodents are summarized to elucidate the dissociable contributions that prefrontal cortical, striatal, thalamic and dopaminergic systems make to different component processes of behavioral flexibility, with an emphasis on set-shifting functions mediated by the medial PFC.
279 citations
••
TL;DR: Based on neurodevelopment hypothesis of schizophrenia, schizophrenia model rats treated with PCP at the perinatal stage is developed and it is suggested that these PCP animal models would be useful for evaluating novel therapeutic candidates and for confirming pathological mechanisms of schizophrenia.
258 citations
Authors
Showing all 920 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hideyuki Okano | 128 | 1169 | 67148 |
Masaaki Terada | 78 | 259 | 17530 |
Takahiro Ochiya | 64 | 309 | 19828 |
Izumu Saito | 56 | 197 | 13288 |
Yutaka Ueda | 48 | 488 | 9028 |
Takahiro Ochiya | 45 | 197 | 10244 |
Takahiro Sato | 43 | 277 | 8133 |
Masaaki Mori | 42 | 412 | 7579 |
Takuro Wada | 41 | 214 | 5677 |
Ryuji Hiramatsu | 31 | 58 | 7323 |
Kiyoshi Furukawa | 31 | 139 | 2636 |
Akihito Hashidzume | 31 | 123 | 4632 |
Shunichiro Kubota | 27 | 88 | 2314 |
Tomohide Tsukahara | 27 | 108 | 2252 |
Hiroshi Itoh | 26 | 93 | 2592 |